Table 1.
IO-IO (n = 99) | IO-TKI (n = 71) | Nivolumab (n = 117) | TKI (n = 276) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Male (n = 71) | Female (n = 28) | p | Male (n = 52) | Female (n = 19) | p | Male (n = 83) | Female (n = 34) | p | Male (n = 199) | Female (n = 77) | p | |
Age, in years ≥ 65 (ref. < 65) | 34 (48%) | 16 (57%) | 0.505 | 33 (63%) | 12 (63%) | 1.000 | 43 (52%) | 25 (74%) | 0.0392 | 96 (48%) | 42 (55%) | 0.421 |
Histopathology Clear-cell RCC (ref. non-clear-cell RCC/ unknown) | 49 (69%) | 21 (75%) | 0.630 | 35 (67%) | 13 (68%) | 1.000 | 69 (83%) | 28 (82%) | 1.000 | 153 (77%) | 57 (74%) | 0.639 |
IMDC risk Favorable Intermediate Poor |
0 49 (69%) 22 (31%) |
0 16 (57%) 12 (43%) |
0.348 |
11 (21%) 29 (56%) 12 (23%) |
2 (11%) 14 (74%) 3 (16%) |
0.378 |
6 (7%) 55 (66%) 22 (27%) |
5 (15%) 17 (50%) 12 (35%) |
0.211 |
24 (12%) 131 (66%) 44 (22%) |
15 (19%) 47 (61%) 15 (19%) |
0.281 |
Treatment line Second (ref. third or more later) | N.A | N.A | N.A | N.A | N.A | 51 (61%) | 20 (59%) | 0.837 | N.A | N.A | N.A | |
Lung metastasis Presence (ref. absence) | 44 (62%) | 19 (68%) | 0.648 | 35 (67%) | 10 (53%) | 0.278 | 55 (66%) | 18 (53%) | 0.210 | 134 (67%) | 46 (60%) | 0.261 |
Bone metastasis Presence (ref. absence) | 16 (23%) | 7 (25%) | 0.796 | 11 (21%) | 4 (21%) | 1.000 | 21 (25%) | 11 (32%) | 0.496 | 46 (23%) | 18 (23%) | 1.000 |
Liver metastasis Presence (ref. absence) | 8 (11%) | 6 (21%) | 0.210 | 9 (17%) | 3 (16%) | 1.000 | 14 (17%) | 5 (15%) | 1.000 | 28 (14%) | 10 (13%) | 1.000 |
Lymph node metastasis Presence (ref. absence) | 23 (32%) | 11 (39%) | 0.639 | 13 (25%) | 4 (21%) | 1.000 | 28 (34%) | 11 (32%) | 1.000 | 59 (30%) | 21 (27%) | 0.768 |
IO immunotherapy, TKI tyrosine kinase inhibitor, RCC renal cell carcinoma, IMDC international metastatic renal cell carcinoma database consortium, N.A. not applicable, ref reference